article thumbnail

The future of CNS drug development: signs of real progress

Drug Target Review

2 A raft of emerging therapeutic modalities sits at the centre of this boom, spanning advanced biologics, engineered platforms and next-generation small molecules. This protective barrier prevents more than 98 percent of small-molecule drugs and all macromolecular therapeutics 3 from accessing the brain.

article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

Moreover, GPCRs have a complex pharmacology, with each acting as a kind of signalling hub for an array of downstream signals, in contrast to simpler receptors which are generally responsible for one signal.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How GPCR agonists, including antibodies, are shaping the future of metabolic care

Drug Target Review

The MC4R-based ConfoGen was used to immunize llamas, resulting in an immune response that generated a highly diverse panel of MC4R-specific agonists. In addition to generating agonistic antibodies, Confo is also successfully applying the ConfoBody/ConfoChimer technology to drugging GPCR with small molecules.

article thumbnail

Outsmarting immune suppression through GPCR innovation

Drug Target Review

These CCR8+ Tregs are known to suppress immune responses in the tumour microenvironment (TME), allowing cancers to grow unchecked. “DT-7012 Whether we are working with small molecules or larger biologics, our platform enables a precise design of innovative drug candidates with highly differentiated profiles.”

article thumbnail

Advancements in hit identification for membrane protein drug discovery

Drug Target Review

Involved in various physiological processes, such as vision, taste, smell, immune response and neurotransmission, GPCRs are activated by various molecules including hormones, neurotransmitters and environmental stimuli, which trigger a cascade of cellular events that help regulate bodily functions.

article thumbnail

Leveraging agonist antibodies to address immunological diseases

Drug Target Review

Agonist antibodies of immune checkpoint regulators These represent a groundbreaking class of immunotherapeutic agents that mimic the natural function of endogenous ligands by binding to specific cell-surface receptors. In these conditions, the goal of therapy is typically to suppress or mitigate immune activity.

article thumbnail

A Visual Guide to Gene Delivery

Codon

And even if all these economic hurdles are overcome, there are still three main technical challenges to solve: cargo capacity, specificity, and immune response. The human immune system is designed to recognize and eliminate foreign material, which unfortunately includes common viral vectors for gene therapy.